Core Insights - Jupiter Neurosciences, Inc. is advancing its FDA-cleared Phase IIa clinical program targeting Parkinson's disease, with a focus on neuroinflammation and central nervous system disorders [2][5] - The company is also generating revenue through its consumer product Nugevia, which utilizes the patented JOTROL technology to enhance resveratrol bioavailability [3][5] Clinical Development - The FDA granted the Investigational New Drug (IND) application for the Phase IIa trial in November 2025, following preclinical data showing a nine-fold improvement in JOTROL bioavailability compared to standard resveratrol formulations [2] - The clinical program is supported by translational proof-of-concept data from Parkinson's disease models, which underpins the scientific rationale for the trial [2] Revenue Generation - Nugevia has demonstrated early commercial validation with a repeat purchase rate of approximately 25% and a product return rate of about 3%, indicating a capital-efficient operating model [3] - The dual-path strategy of combining clinical development with revenue generation through Nugevia differentiates Jupiter from other biotechnology peers that rely solely on external financing [3][5] Management's Outlook - The CEO expressed confidence in the company's execution plan and the importance of achieving clinical milestones while continuing to build revenue through Nugevia [4] - Management will engage with investors and potential partners at the BIO Investment and Growth Summit 2026, highlighting the company's commitment to disciplined execution [3][4]

Core Viewpoint - Jupiter Neurosciences, Inc. is actively engaging with investors to discuss its clinical advancements and commercial strategies, particularly in neuroinflammation and central nervous system disorders [1][3][4]. Group 1: Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and central nervous system disorders [5]. - The company's lead clinical program is advancing through a Phase IIa trial in Parkinson's disease [5]. - Jupiter is commercializing Nugevia™, a consumer product based on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability [5]. Group 2: Investor Engagement - The company has been invited to present at a private investor dinner, the only company to do so, indicating its unique position and potential interest from investors [1][2]. - The event will feature discussions with accredited and high net worth investors about emerging investment opportunities [2]. - Jupiter's management intends to provide updates on clinical progress, commercial strategy, and long-term objectives, including the advancement of the Phase IIa Parkinson's program and broader development initiatives [3][4]. Group 3: Strategic Approach - Jupiter's strategy combines clinical development with active commercial revenue generation, reflecting a dual-path approach [4][5]. - The company emphasizes direct engagement with the investment community as part of its philosophy to remain accessible and transparent [4].

Core Economic Terms - Jupiter Neurosciences, Inc. has deferred the commencement of repayment for its financing to April 1, 2026, while the core economic terms of the $6.0 million financing remain unchanged [1][2][8] - The amendment does not introduce new pricing provisions, reset features, or additional financing commitments, focusing solely on installment timing and application mechanics [2] Strategic Alignment - The amendment reflects a strategic decision between Jupiter and Yorkville, demonstrating Yorkville's commitment to Jupiter's long-term strategy by adjusting installment timing without altering pricing or other economic terms [3] - This alignment allows the company to focus on advancing its Phase II Parkinson's program and scaling its product Nugevia™, which is generating commercial cash flow [3] Commercial Performance - Jupiter's strategy combines clinical development with active commercial revenue generation, with Nugevia™ showing repeat purchase activity of approximately 25% and product return rates of about 3% [3] - The company believes that early commercial validation, along with continued clinical progress, strengthens its capital profile and differentiates it from biotechnology peers reliant solely on capital markets funding [3] Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and central nervous system disorders, with its lead clinical program in a Phase IIa trial for Parkinson's disease [5] - The company is also commercializing Nugevia™, a consumer product based on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability [5]

Core Insights - Jupiter Neurosciences, Inc. is launching a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ product line, which focuses on metabolic, mitochondrial, and neuroinflammatory health [1][2] Group 1: Company Strategy - The company is pursuing a dual-engine strategy that combines a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business, aiming to capitalize on the growing adoption of GLP-1 therapies globally [2] - Jupiter believes that the physiological demands placed on individuals undergoing GLP-1-induced weight loss represent an unmet need, as many seek solutions for long-term metabolic resilience and healthspan [3] Group 2: Product Development - The Nugevia product line is designed to address the biological stresses associated with rapid metabolic changes, particularly focusing on mitochondrial health, neuroinflammation, and cellular resilience [4] - Jupiter's proprietary formulation, JOTROL, enhances the bioavailability of resveratrol and supports mental clarity, skin health, and mitochondrial function, positioning Nugevia as a clinical-grade supplement [5] Group 3: Market Context - The rise of GLP-1 receptor agonists has significantly transformed the landscape of obesity and metabolic health, with increasing awareness of the physiological impacts of weight loss on individuals [3] - The Aesthetic Surgery Journal reported that patients with significant weight loss may appear up to 5 years older than their peers, highlighting the need for supportive solutions like Nugevia [4]

Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a patented resveratrol-based platform aimed at addressing neuroinflammation and promoting healthy aging [3] - The company is pursuing a dual-path strategy that includes a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, as well as a consumer longevity market through its Nugevia product line [3] - JOTROL™ has shown significantly improved bioavailability, enhancing its therapeutic potential [3] Upcoming Event - Jupiter Neurosciences will participate in the DealFlow Discovery Conference on January 28-29, 2026, where the Chairman and CEO, Christer Rosén, will present the company and hold one-on-one investor meetings [1][2] - Investors can attend the conference at no cost and are encouraged to schedule meetings with the management team [2] Product Pipeline - The company's prescription pipeline is currently focused on CNS disorders, with a Phase IIa clinical trial ongoing for Parkinson's disease, and includes indications for Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS [3] - Nugevia, the consumer product line, aims to bring clinical-grade science to the supplement market, supporting mental clarity, skin health, and mitochondrial function [3]

Core Viewpoint - Jupiter Neurosciences, Inc. is hosting a webinar to discuss its scientific platform, clinical development plans, and commercial strategy for 2026, focusing on its lead asset JOTROL™ and its dual-path approach in both pharmaceutical and consumer markets [2][4]. Group 1: Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company targeting neuroinflammation and healthy aging through a dual-path strategy [4]. - The company is advancing a therapeutic pipeline for central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [4]. - JOTROL™, a proprietary enhanced resveratrol formulation, has shown significantly improved bioavailability compared to earlier resveratrol products [4][5]. Group 2: JOTROL™ and Clinical Development - JOTROL™ achieves over nine times higher bioavailability compared to previous resveratrol formulations, which is critical for its effectiveness [6]. - The company is advancing JOTROL™ toward a Phase IIa clinical trial in Parkinson's Disease, with a broader focus on CNS disorders including Alzheimer's Disease and Friedreich's Ataxia [4][6]. - The Phase I study results of JOTROL™ were published in reputable journals, indicating a strong foundation for upcoming trials [6]. Group 3: Nugevia Product Line - Nugevia™ is a premium longevity and performance supplement line that utilizes the same patented JOTROL™ technology, targeting cognitive health, skin vitality, and cellular energy [8][9]. - Nugevia products are developed under pharmaceutical standards and are based on peer-reviewed clinical data, differentiating them from conventional supplements [9]. - The product line aims to support healthy aging through formulations that enhance cognitive resilience, mitochondrial energy, and skin vitality [8].

Core Insights - Jupiter Neurosciences, Inc. is focused on treatments for neuroinflammation and rare diseases using its patented resveratrol delivery platform, JOTROL [1] - The company has a clinical pipeline with over $50 billion in combined market opportunities [1] Company Overview - Christer Rosen is the Co-Founder, CEO, and Chairman of Jupiter Neurosciences since January 1, 2016, with a background in founding and leading multiple businesses [2] - Rosen previously founded EffRx Pharmaceuticals, where he developed the osteoporosis drug Binosto, which received FDA and EU approvals [2] - Alison Silva serves as the President and Chief Business Officer of Jupiter Neurosciences, with extensive experience in drug development and regulatory strategy [4] - Silva has held leadership roles in various biotech companies, including Cotinga Pharmaceuticals and Synlogic, and has a strong background in orphan drug strategy [4][5]

Core Insights - Jupiter Neurosciences is advancing its JOTROL platform into a Phase 2a clinical trial for Parkinson's disease, marking a significant regulatory milestone with FDA clearance [4][5] - The company launched its Nugevia consumer brand, targeting the $8 trillion longevity market, with initial products designed to enhance brand visibility and generate revenue [6][7] - Jupiter has secured strategic financing of up to $20 million to support its clinical and commercial initiatives, providing flexibility and control over capital access [10][11][12] Company Achievements - Jupiter Neurosciences completed its first full year as a public company, establishing a foundation for long-term value creation and executing major initiatives [2][3] - The JOTROL platform has demonstrated a nine-fold improvement in bioavailability and effective blood-brain barrier penetration, supporting its therapeutic potential [5][20] - The Nugevia product line includes three initial offerings—GLO, PWR, and MND—integrating JOTROL with other bioavailable ingredients to support various aspects of health [7][21] Market Positioning - The Nugevia brand is supported by high-profile ambassadors, enhancing its market presence and performance-driven identity [8] - A dedicated website for Nugevia was launched, facilitating pre-orders and establishing a subscription-based model for recurring revenue [9] - Jupiter's dual-path strategy focuses on both therapeutic applications for CNS disorders and consumer longevity products, positioning the company for growth in both sectors [17][22] Financial Strategy - The strategic financing agreement with Yorkville Advisors allows Jupiter to access capital as needed, ensuring stability during its growth phase [10][11] - The financing structure is designed to be non-toxic and fully controlled by the company, allowing for advantageous capital access [11][12] - The company aims to strengthen its financial position while supporting ongoing operations and clinical trials without compromising shareholder interests [12]

Core Insights - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a resveratrol-based therapeutic platform aimed at neuroinflammation and mitochondrial dysfunction [1][4] - The company will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, providing opportunities for one-on-one meetings with investors [1][2] Company Overview - Jupiter Neurosciences is pursuing a dual-path strategy to address neuroinflammation and promote healthy aging, targeting CNS disorders and rare diseases while also entering the consumer longevity market with its Nugevia product line [4] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and indications such as Alzheimer's Disease and Friedreich's Ataxia [4] Product Details - JOTROL™ has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval for resveratrol [6] - The Nugevia product line leverages the same clinically validated delivery technology as JOTROL™, offering support for cognitive health, skin vitality, and cellular energy [7]

As filed with the Securities and Exchange Commission on November 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Jupiter Neu ...